BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) hit a new 52-week high on Thursday after JPMorgan Chase & Co. raised their price target on the stock from $321.00 to $345.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. BeOne Medicines traded as high as $298.00 and last traded at $294.00, with a volume of 154254 shares trading hands. The stock had previously closed at $279.16.
ONC has been the topic of several other research reports. Wall Street Zen lowered shares of BeOne Medicines from a "buy" rating to a "hold" rating in a research note on Saturday, July 12th. TD Securities reissued a "buy" rating and issued a $334.00 price target on shares of BeOne Medicines in a report on Thursday, April 24th. Royal Bank Of Canada boosted their price objective on BeOne Medicines from $311.00 to $349.00 and gave the company an "outperform" rating in a research report on Wednesday. Morgan Stanley increased their target price on BeOne Medicines from $313.00 to $330.00 and gave the stock an "overweight" rating in a research report on Friday, June 27th. Finally, Guggenheim boosted their price target on shares of BeOne Medicines from $348.00 to $350.00 and gave the company a "buy" rating in a report on Thursday, May 8th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $327.56.
Read Our Latest Research Report on ONC
Insiders Place Their Bets
In other BeOne Medicines news, COO Xiaobin Wu sold 1,363 shares of the business's stock in a transaction that occurred on Monday, June 23rd. The shares were sold at an average price of $260.00, for a total value of $354,380.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Lai Wang sold 1,028 shares of the stock in a transaction dated Monday, June 23rd. The shares were sold at an average price of $260.00, for a total value of $267,280.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 137,573 shares of company stock worth $34,156,799. 6.62% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. PFG Investments LLC acquired a new position in BeOne Medicines during the 2nd quarter worth about $238,000. Janney Montgomery Scott LLC bought a new position in shares of BeOne Medicines in the 2nd quarter valued at about $373,000. LVW Advisors LLC bought a new stake in shares of BeOne Medicines during the second quarter worth approximately $247,000. Signaturefd LLC acquired a new stake in BeOne Medicines during the 2nd quarter worth $49,000. Finally, Perigon Wealth Management LLC bought a new stake in shares of BeOne Medicines during the 2nd quarter valued at $581,000. Institutional investors and hedge funds own 48.55% of the company's stock.
BeOne Medicines Trading Up 1.4%
The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.71 and a current ratio of 1.96. The company's 50 day simple moving average is $250.96. The company has a market capitalization of $32.28 billion, a P/E ratio of -79.18 and a beta of 0.28.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $1.93. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. The business had revenue of $1.12 billion during the quarter, compared to analysts' expectations of $1.12 billion. On average, equities analysts forecast that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current fiscal year.
BeOne Medicines Company Profile
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Recommended Stories
Before you consider BeOne Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.
While BeOne Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access